Intercept Pharmaceuticals Inc
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, is developing obeticholic acid (OCA), an agonist of the farnesoid X receptor, which is in Phase III clinical trials for the treatment of primary biliary cirrhosis; OCA that is in Phase IIb clinical trials for treating nonalcoholic steatohepatitis; and OCA that is Phase II clinical trial to treat fibrosing cholestatic hepatitis. The company was incorporated in 2002 and is headquartered in New York, New York.
Latest events on Quartr
Previous Events for Intercept Pharmaceuticals Inc
United States of America